Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2011-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4088/JCP.09m05723bluPMID 20868642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report.

  2012cited by this paper
• Duloxetine in Affective Disorders: a Naturalistic Study on Psychiatric and Medical Comorbidity, Use in Association and Tolerability Across Different Age Groups

  2012cited by this paper
• Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods

  2009cited by this paper
• Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

  2007cited by this paper
• Patterns of depressive symptom response in duloxetine‐treated outpatients with mild, moderate or more severe depression

  2007cited by this paper
• Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.

  2007cited by this paper
• Prospective study of risk factors for attempted suicide among patients with DSM–IV major depressive disorder

  2005cited by this paper
• Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder.

  2005cited by this paper
• Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.

  2004cited by this paper
• The Hamilton Depression Rating Scale: has the gold standard become a lead weight?

  2004cited by this paper
• Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.

  2004cited by this paper
• Duloxetine in the long-term treatment of major depressive disorder.

  2003cited by this paper
• The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

  2003cited by this paper
• Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression

  2002cited by this paper
• The impact of depression on the well‐being, disability and use of services in older adults: a longitudinal perspective

  2002cited by this paper
• Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.

  2002cited by this paper
• Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.

  2002cited by this paper
• Longitudinal investigation of depression outcomes in primary care in six countries: the LIDO Study. Functional status, health service use and treatment of people with depressive symptoms

  2002cited by this paper
• Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

  2002cited by this paper
• Severe Depression

  2001cited by this paper
• Major Depression: Does a Gender-Based Down-Rating of Suicide Risk Challenge Its Diagnostic Validity?

  2001cited by this paper
• Mirtazapine Versus Venlafaxine in Hospitalized Severely Depressed Patients With Melancholic Features

  2001cited by this paper
• The responsiveness of the Hamilton Depression Rating Scale.

  2000cited by this paper
• Treatment of severe depression.

  2000cited by this paper
• Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology.

  1999cited by this paper
• Lifetime suicide risk in major depression: sex and age determinants.

  1999cited by this paper
• Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs.

  1999cited by this paper
• A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.

  1998cited by this paper
• Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine.

  1997cited by this paper
• Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline.

  1997cited by this paper
• A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression

  1996cited by this paper
• Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo.

  1995cited by this paper
• Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia.

  1995cited by this paper
• A double‐blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia

  1994cited by this paper
• The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants

  1994cited by this paper
• The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations?

  1994cited by this paper
• Adverse events and treatment discontinuations in fluoxetine clinical trials

  1993cited by this paper
• Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study.

  1993cited by this paper
• Fixed-dose fluoxetine therapy for depression.

  1987cited by this paper
• The Hamilton Depression Scale

  1981cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• QUANTITATIVE RATING OF DEPRESSIVE STATES

  1975cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Therapeutic reference range for duloxetine in the treatment of depression revised: A systematic review and meta-analysis

  2024cites this paper
• Dose-Response Relationship in Selective Serotonin and Norepinephrine Reuptake Inhibitors in the Treatment of Major Depressive Disorder: A Meta-Analysis and Network Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine

  2020cites this paper
• Dose‐response relationship of selective serotonin reuptake inhibitors

  2020cites this paper
• Duloxetine plasma level and antidepressant response

  2019cites this paper
• Drug Augmentation for Treatment-refractory Major Depressive Disorder

  2018cites this paper
• Evidence-based pharmacotherapy of treatment-resistant unipolar depression

  2017cites this paper
• Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder

  2016cites this paper
• Suicidal thoughts and reasons for living in hospitalized patients with severe depression: post-hoc analyses of a double-blind randomized trial of duloxetine.

  2014cites this paper
• Is There a Role for Switching Antidepressants in Treatment‐resistant Depression?

  2013cites this paper
• Pharmacological interventions for treatment-resistant depression in adults.

  2013cites this paper
• Duloxetine in Affective Disorders: a Naturalistic Study on Psychiatric and Medical Comorbidity, Use in Association and Tolerability Across Different Age Groups

  2012cites this paper
• Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.

  2012cites this paper
• Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report.

  2012cites this paper
• Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.

  2010influential citation